GLPwatch
Putting More Weight on Obesity Trials in Heart Failure.
Curr Heart Fail Rep · 2024
Last updated 2026-05-28A review of recent studies found that the GLP-1 drug semaglutide helped people with heart failure and obesity lose weight and improved their health status, as measured by a quality-of-life survey and a walking test. Future trials will test semaglutide and another drug, tirzepatide, in people with heart failure across different types of heart function.
AI summary of the abstract below.
| Journal | Curr Heart Fail Rep, 2024 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.24 |
| NIH percentile | 15 |
| Molecules | — |
| Conditions studied | Obesity, Heart Failure |
Abstract
PURPOSE OF REVIEW: To review ongoing and planned clinical trials of weight loss among individuals with or at high risk of heart failure.
RECENT FINDINGS: Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fraction and obesity significantly improves weight loss and health status as assessed by the KCCQ-CSS score and is associated with improvements in 6-min walk test. Ongoing and planned trials will explore the role of intentional weight loss with treatments such as semaglutide or tirzepatide for individuals with heart failure across the entire ejection fraction spectrum.
Verbatim abstract via PubMed 38619690 ↗